Inclisiran’s Safety Data Suggest Game-Changing Potential In PCSK9 Market

The Medicines Co. unveiled Phase III safety data for inclisiran showing safety and tolerability comparable to placebo and efficacy in line with the PCSK9 inhibitor class – which should be the reassurance it needs for the oral agent.